@article{b76c5b060fea4988a038fec528121f87,
title = "Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response",
abstract = "Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval-halving compared with dose-doubling.",
author = "Lior Katz and Gisbert, {Javier P} and Beth Manoogian and Kirk Lin and Casper Steenholdt and Mantzaris, {Gerassimos J} and Ashish Atreja and Yulia Ron and Arun Swaminath and Somal Shah and Ailsa Hart and Lakatos, {Peter Laszlo} and Pierre Ellul and Eran Israeli and Svendsen, {Mads Naundrup} and {van der Woude}, {C Janneke} and Katsanos, {Konstantinos H} and Laura Yun and Tsianos, {Epameinondas V} and Torben Nathan and Maria Abreu and Iris Dotan and Bret Lashner and Jorn Brynskov and Terdiman, {Jonathan P} and Higgins, {Peter D R} and Maria Chaparro and Shomron Ben-Horin",
note = "Copyright {\textcopyright} 2012 Crohn's & Colitis Foundation of America, Inc.",
year = "2012",
doi = "10.1002/ibd.22902",
language = "English",
volume = "18",
pages = "2026--33",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John/Wiley & Sons, Inc",
number = "11",
}